 BRISBANE, Calif., May 02, 2022 GLOBE NEWSWIRE -- Vera Therapeutics, Inc. Nasdaq: VERA, a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that interim data from the Phase 2 trial of MAU868 versus placebo to treat BK Virus BKV in kidney transplant patients will be delivered in a late-breaking oral presentation at the American Transplant Congress ATC 2022 in Boston, Massachusetts. 